Potent inhibitor of poly(ADP-ribose) polymerase (PARP) (EC50
= 20 nM). ~1000-fold more potent than 3-Aminobenzamide
(Cat. No. 0788). Protects primary neuronal cells from oxygen-glucose deprivation in vitro
and reduces infarct size following focal cerebral ischemia in vivo
. Displays protective effects against cisplatin
-induced kidney injury. Also displays activity at Pim-1 and Pim-2 kinases at higher concentrations (IC50
values are 3.7 and 16 μ
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
All Tocris products are intended for laboratory research use only.
Protective effects of PJ34, a novel, potent inhibitor of poly(ADP-ribose) polymerase (PARP) in in vitro and in vivo models of stroke.
Abdelkarim et al.
Poly(ADPR)polymerase inhibition and apoptosis induction in cDDP-treated human carcinoma cell lines.
Gambi et al.
Poly(ADP-ribose) polymerase 1 activation is required for cisplatin nephrotoxicity.
Kim et al.
Kidney Int., 2012;82:193
Identification of Pim kinases as novel targets for PJ34 with confounding effects in PARP biology.
Antolin et al.
ACS Chem.Biol., 2012;7:1962
The citations listed below are publications that use Tocris products. Selected citations for PJ 34 hydrochloride include:
Showing Results 1 - 1 of 1